申请人:Pfizer Inc.
公开号:US04252812A1
公开(公告)日:1981-02-24
2-Substituted-5-aryl-2,3,4,4a,5,9b-hexahydro-1H-pyrido[4,3-b]indoles of the formula (I): ##STR1## and the pharmaceutically-acceptable salts thereof, wherein the hydrogen atoms in the 4a position and 9b positions are in a trans relationship to each other and the 5-aryl-2,3,4,4a,5,9b-hexahydro-1H-pyrido[4,3-b]indole moiety is dextrorotatory; X.sub.1 and Y.sub.1 are the same or different and are each hydrogen or fluoro; Z.sub.1 is hydrogen, fluoro or methoxy; M is a member selected from the group consisting of ##STR2## a mixture thereof and C=0 and n is 3 or 4; their use as tranquilizing agents, pharmaceutical compositions containing them and a process for their production.
式(I)的2-取代-5-芳基-2,3,4,4a,5,9b-六氢-1H-吡啶[4,3-b]吲哚及其药学上可接受的盐,其中4a位和9b位的氢原子相对构型为反式,5-芳基-2,3,4,4a,5,9b-六氢-1H-吡啶[4,3-b]吲哚基团为右旋性;X.sub.1和Y.sub.1相同或不同,分别为氢或氟;Z.sub.1为氢、氟或甲氧基;M为从以下组中选择的成员之一:##STR2## 其混合物和C=0,n为3或4;它们作为镇静剂的用途,包含它们的制药组合物以及它们的制备方法。